CervoMed (CRVO) Stock Price, News & Analysis

Company Overview

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $3.04 to $3.25
• 50-Day Range: $2.87 to $4.24
• 52-Week Range: $2.82 to $13.13
• Volume: 57,997 shs
• Average Volume: 72,513 shs
• Market Capitalization: $28.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.60
• Consensus Rating: Moderate Buy

CervoMed Stock Analysis - MarketRank™

CervoMed scored higher than 67% of companies evaluated by MarketBeat, and ranked 311th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CervoMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CervoMed has a consensus price target of $22.60, representing about 631.4% upside from its current price of $3.09.

Amount of Analyst Coverage

CervoMed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CervoMed are expected to grow in the coming year, from ($2.88) to ($2.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CervoMed is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CervoMed is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CervoMed has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.65% of the float of CervoMed has been sold short.

Short Interest Ratio / Days to Cover

CervoMed has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in CervoMed has recently decreased by 1.42%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CervoMed does not currently pay a dividend.

Dividend Growth

CervoMed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.46

News Sentiment

CervoMed has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for CervoMed this week, compared to 4 articles on an average week.

Search Interest

10 people have searched for CRVO on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added CervoMed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CervoMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.40% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

25.15% of the stock of CervoMed is held by institutions.

Company Calendar

• Last Earnings: 5/18/2026
• Today: 5/29/2026
• Next Earnings (Estimated): 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRVO
• Previous Symbol: NASDAQ:CRVO
• CIK: 1053691
• Web: diffusionpharma.com
• Phone: 14342200718
• Fax: 434-220-0722
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CervoMed: $22.60
• High Price Target: $31.00
• Low Price Target: $9.00
• Potential Upside/Downside: +637.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.97 million
• Net Margins: -672.80%
• Pretax Margin: -1,437.13%
• Return on Equity: -136.08%
• Return on Assets: -112.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.36
• Quick Ratio: 3.36

Sales & Book Value

• Annual Sales: $4.01 million
• Price / Sales: 7.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.15 per share
• Price / Book: 2.67

Miscellaneous

• Outstanding Shares: 9,260,000
• Free Float: 5,981,000
• Market Cap: $28.39 million
• Optionable: Not Optionable
• Beta: -0.63